Cellistic emtered into asset purchase agreement to acquire Manufacturing Business Unit of Celyad Oncology from Celyad Oncology SA (ENXTBR:CYAD) for €6 million on September 20, 2022. The transaction is subject to a number of customary conditions and is anticipated to close in the fourth quarter of this year. Pierre-Olivier Mahieu and Sophie Rutten of Allen & Overy LLP (Brussels) acted as legal advisor to Celyad Oncology SA (ENXTBR:CYAD).

Cellistic completed the acquisition of Manufacturing Business Unit of Celyad Oncology from Celyad Oncology SA (ENXTBR:CYAD) in September 2022.